Breaking News

Takeda, Arbor Enter Licensing Deal

Arbor to develop and market blood pressure products for U.S. market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda Pharmaceutical Co. Ltd. and Arbor Pharmaceuticals Ireland Ltd. have entered into a license, development and commercialization agreement providing Arbor with exclusive rights to market EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Takeda will receive an upfront payment along with future milestone and royalty payments based on sales.   “This is an opportunity to capture the value that we’ve created in developing and launching ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters